Effect of Dorzagliatin on Renal Function Outcomes in People With Type 2 Diabetes: a Multicentric, Prospective, Randomized Study.
A Multicentric, Prospective, Randomized Study Evaluating the Improvement of Renal Function Outcomes With Dorzagliatin in Patients With Type 2 Diabetes Mellitus With Early Kidney Injury.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210008
- Division of Endocrinology, the Affiliated Drum Tower Hospital of Nanjing University
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age:18-75 years old, male and female.
- Patients with type 2 diabetes mellitus, type 2 diabetes mellitus diagnosis criteria: according to the "Chinese Type 2 Diabetes Mellitus Prevention and Treatment Guide (2020 Edition).
- UACR 30-299mg/g.
- eGFR ≥60mL/min/1.73m².
- HbA1c 7.0-10.5%.
Exclusion Criteria:
- Pregnant and lactating women and women of childbearing age who do not want to take reliable contraceptive measures.
- Known allergic history to dorzagliatin/gliclazide/metformin.
- Diabetic acute and chronic complications, including diabetic ketoacidosis, a hyperglycemic hyperosmolar state or hypoglycemic coma, etc.
- Serious impairment of heart, liver, kidney and other organs.
- With hypertension(≥140/90mmHg).
- Fasting C-peptide <300pmol/L.
- Contraindications of MRI examination, such as implantation of metal prosthesis in vivo, claustrophobia, wearing insulin pumps, etc.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Patients treat with Dorzagliatin
Dorzagliatin will be initiated and maintained at 75mg twice a day until the completion of the study.
Meanwhile, all patients will also continue on regimen of metformin 500mg three times a day throughout the study.
Visits at 4-week intervals will be performed to evaluate the safety of drugs.
|
Dorzagliatin will be initiated and maintained at 75mg twice a day
|
|
Active Comparator: Patients treat with Gliclazide
Gliclazide will be initiated and maintained at 30mg once a day until the completion of the study.
Meanwhile, all patients will also continue on regimen of metformin 500mg three times a day throughout the study.
Visits at 4-week intervals will be performed to evaluate the safety of drugs.
|
Gliclazide will be initiated and maintained at 30mg once a day
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participants' personal information
Time Frame: 1 day
|
Self-reported information (age in years, gender,course of disease )
|
1 day
|
|
Physical assessments
Time Frame: 1 day
|
BMI (body mass index) in kg/m^2
|
1 day
|
|
renal function
Time Frame: 1 day
|
changes of renal function (eGFR, creatinine, cystatin C, TNF-1)
|
1 day
|
|
renal magnetic resonance imaging(MRI)
Time Frame: 1 day
|
Changes of perirenal fat content, renal proton density fat fraction and degree of renal fibrosis
|
1 day
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
blood sugar
Time Frame: 1 day
|
fasting blood sugar、2-hour postprandial blood sugar
|
1 day
|
|
insulin
Time Frame: 1 day
|
fasting insulin、2-hour insulin
|
1 day
|
|
HOMA2-β
Time Frame: 1 day
|
20*fasting insulin(mIU/L)/(fasting blood sugar(mmol/L)-3.5)
|
1 day
|
|
HOMA2-IR
Time Frame: 1 day
|
fasting blood sugar(mmol/L)*fasting insulin(mIU/L)/22.5
|
1 day
|
|
HOMA2-IS
Time Frame: 1 day
|
22.5/fasting blood sugar(mmol/L)*fasting insulin(mIU/L)
|
1 day
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Yang W, Zhu D, Gan S, Dong X, Su J, Li W, Jiang H, Zhao W, Yao M, Song W, Lu Y, Zhang X, Li H, Wang G, Qiu W, Yuan G, Ma J, Li W, Li Z, Wang X, Zeng J, Yang Z, Liu J, Liang Y, Lu S, Zhang H, Liu H, Liu P, Fan K, Jiang X, Li Y, Su Q, Ning T, Tan H, An Z, Jiang Z, Liu L, Zhou Z, Zhang Q, Li X, Shan Z, Xue Y, Mao H, Shi L, Ye S, Zhang X, Sun J, Li P, Yang T, Li F, Lin J, Zhang Z, Zhao Y, Li R, Guo X, Yao Q, Lu W, Qu S, Li H, Tan L, Wang W, Yao Y, Chen D, Li Y, Gao J, Hu W, Fei X, Wu T, Dong S, Jin W, Li C, Zhao D, Feng B, Zhao Y, Zhang Y, Li X, Chen L. Dorzagliatin add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med. 2022 May;28(5):974-981. doi: 10.1038/s41591-022-01803-5. Epub 2022 May 12.
- Simons PIHG, Simons N, Stehouwer CDA, Schalkwijk CG, Schaper NC, Brouwers MCGJ. Association of common gene variants in glucokinase regulatory protein with cardiorenal disease: A systematic review and meta-analysis. PLoS One. 2018 Oct 23;13(10):e0206174. doi: 10.1371/journal.pone.0206174. eCollection 2018.
- Hishida A, Takashima N, Turin TC, Kawai S, Wakai K, Hamajima N, Hosono S, Nishida Y, Suzuki S, Nakahata N, Mikami H, Ohnaka K, Matsui D, Katsuura-Kamano S, Kubo M, Tanaka H, Kita Y. GCK, GCKR polymorphisms and risk of chronic kidney disease in Japanese individuals: data from the J-MICC Study. J Nephrol. 2014 Apr;27(2):143-9. doi: 10.1007/s40620-013-0025-0. Epub 2013 Dec 17.
- Wang K, Shi M, Yang A, Fan B, Tam CHT, Lau E, Luk AOY, Kong APS, Ma RCW, Chan JCN, Chow E. GCKR and GCK polymorphisms are associated with increased risk of end-stage kidney disease in Chinese patients with type 2 diabetes: The Hong Kong Diabetes Register (1995-2019). Diabetes Res Clin Pract. 2022 Nov;193:110118. doi: 10.1016/j.diabres.2022.110118. Epub 2022 Oct 13.
- Lin L, Dekkers IA, Huang L, Tao Q, Paiman EHM, Bizino MB, Jazet IM, Lamb HJ. Renal sinus fat volume in type 2 diabetes mellitus is associated with glycated hemoglobin and metabolic risk factors. J Diabetes Complications. 2021 Sep;35(9):107973. doi: 10.1016/j.jdiacomp.2021.107973. Epub 2021 Jun 15.
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Kidney Diseases
- Urologic Diseases
- Endocrine System Diseases
- Diabetes Complications
- Diabetes Mellitus
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Male Urogenital Diseases
- Diabetic Nephropathies
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Gliclazide
Other Study ID Numbers
Other Study ID Numbers
- BY2023
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.